Kadcyla (ado-trastuzumab emtansine)

Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...

Her2 Receptor Antagonists

Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab)...

Antibody Drug Conjugates ADC

The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...

Breast Cancer

Breast cancer in the UK is diagnosed in nearly  46,000 people  each year, with just over 12,000 dying from breast cancer each year in he UK. There are several risk factors for developing b...

Top 50 Biopharma Products 2011

Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...

Injectable Herceptin on the Horizon for HER2 Breast Cancer Patients

FIRST PERSON | An injectable form of Herceptin may be available to patients with HER2 positive breast cancer in the near future. Injectable Herceptin has many benefits over the traditionally IV-admini...

Why Immunogen Is Undervalued

ByJohn Li:Immunogen's (IMGN) current valuation is based on analysts' projected T-DM1 sales in the near future. T-DM1 has a FDA PDUFA data of February 26, 2013. The FDA approval is very likely since in...

Herceptin Is More Dangerous to the Heart Than Previously Reported

FIRST PERSON | The breast cancer drug Herceptin causes more incidence of heart problems than previously thought. This increase is most noticeable in women over the age of 60 and in women who take a co...

One Year On Herceptin For Breast Cancer Ideal

Patients in early-stage HER2-positive breast cancer should remain on Herceptin (trastuzumab) treatment for one year, and not two years or six months, according to a final analysis of the Phase III HER...

Deal struck over development of Herceptin biosimilar

Netherlands-based biopharmaceutical company Synthon announced on 18 July 2012 that it has entered into a global licensing agreement with Amgen and Watson Pharmaceuticals for the clinical development a...

UPDATE 2-Cancer trials show 1 year on Roche's Herceptin is best

* Experts say key message is one year of Herceptin is best

New Herceptin formulation allows delivery via injection

A new formulation of Genetech’s breast cancer drug Herceptin means patients could soon receive treatment via injection, rather than time consuming intravenous drip.

Herceptin May Carry Higher Heart Risks for Women Than Thought

By Kathleen Doheny HealthDay Reporter THURSDAY, Nov. 15 (HealthDay News) -- The risks of developing heart problems while taking the breast cancer drug Herceptin alone or with other a...

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.

The HER3 protein contributes to malignant transformation in breast and other cancer types as a consequence of elevated levels of expression, particularly in the presence of the HER2 protein. We show h...

Bioconjugated Fluorescent Polymeric Nanoparticles for Imaging and Targeted Therapy of HER2-Overexpressing Cancer Cells.

We report the development of Herceptin-conjugated fluorescent polymeric nanoparticles (PNp) probes. Synthesis of fluorescent conjugated polymer as the core, preparation of the core/shell PNp, the abil...

Immobilization of a HER2 Mimotope-derived Synthetic Peptide on Au and Its Potential Application for Detection of Herceptin in Human Serum by QCM.

Therapeutic antibodies are antigenically similar to human antibodies and are difficult to detect in assays of human serum samples without the use of the therapeutic antibody's complementary antigen. H...

Targeted Nanoparticles Assembled via Complexation of Boronic Acid-Containing Targeting Moieties to Diol-Containing Polymers.

The delivery of therapeutics via nanoscaled vehicles for solid cancer treatment can be enhanced by the incorporation of a targeting capability. Here, we describe a new method for assembling a targeted...

Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells.

To study the agricultural production of biosimilar antibodies, trastuzumab (Herceptin) was expressed in Nicotiana benthamiana using the magnICON viral-based transient expression system. Immunoblot ana...